Volume: 6 Issue: 3
Year: 2018, Page: 87-89,
Introduction :A 17-year-old female with sickle cell disease (SCD) presented with vasoocclusive crisis and jaundice, she received conventional treatment and one unit of compatible PRBC after a negative antibody screen was documented. After 48hrs of receiving a blood transfusion, her clinical picture was consistent with hemolysis. Immunohematology workup demonstrated evidence of a new antibody i.e anti-E. Delayed hemolytic transfusion reaction (DHTR) is a well-known complication of RBC transfusion. As her hemoglobin was declining , she was transfused with E antigen negative PRBCs. Despite this, hemolysis was ongoing and accelerated. Thus she was treated with steroids for presumed hyperhemolysis. Clinicians should have a high index of suspicion for hyperhemolysis in sickle cell patients with evidence of hemolysis after a recent transfusion. Differentiating hyperhemolysis from other hemolytic syndromes in SCD patient is critical; transfusions in a hyperhemolytic episode can accelerate hemolysis causing life-threatening anemia.
Keywords: Delayed hemolytic transfusion reaction , hyperhemolysis , Antibody screening, red blood cell, Hemoglobin.
1. Rosse WF, Gallagher D, Kinney T, Castro O, Dosik H, Moohr J, Wang W, Levy PS. Transfusions and alloimmunization in sickle cell disease. The cooperative study of sickle cell disease. Blood 1990 Oct 1;76(7):1431–7.
2. Castro O, Sandler SG, Houston-Yu P, Rana S. Predicting the effect of transfusion only phenotype-matched RBCs to patients with SCD; theoretical and practical implications. Transfusion 2002;42:684–690.
3. Aygun B, Padmanabhan S, Paley C, Chandrasekaran V. Clinical significance of RBC alloantibodies and autoantibodies in sickle cell patients who received transfusions. Transfusion 2002;42:37–43.
4. Fabron A, Jr, Moreira G, Jr, Bordin JO. Delayed hemolytic transfusion reaction presenting as a painful crisis in a patient with sickle cell anemia. Sao Paulo Med J 1999;117(1):38–39.
5. Kalyanaraman M, Heidemann SM, Sarnaik AP, Meert KL, Sarnaik SA. Anti-s antibody-associated delayed hemolytic transfusion reaction in patients with sickle cell anemia. J Pediatr Hematol Oncol 1999;21(1):70–73.
6. Talano JA, Hillery CA, Gottschall JL, et al. Delayed hemolytic transfusion reaction/hyperhemolysis syndrome in children with sickle cell disease. Pediatrics 2003; 111 (6 Pt 1): e661-e665.
7. Garratty G. Severe reactions associated with transfusion of patients with sickle cell disease. Transfusion 1997; 37: 357–61.
8. Petz LD, Calhoun L, Shulman IA, Johnson C, Herron RM. The sickle cell hemolytic transfusion reaction syndrome. Transfusion 1997;37(4):382-392.
9. Win N. Hyperhemolysis syndrome in sickle cell disease. Expert Rev Hematol 2009;2(2):111–115.
10. Cox J, Steane E, Cunningham G, Frenkle E. Risk of alloimmunization and delayed hemolytic transfusion reactions in patients with sickle cell disease. Arch Intern Med 1988;148:2485–2489.
11. Win N., Yeghen T., Needs M., Chen F.E., Okpala I. Use of intravenous immunoglobulin and intravenous methylprednisolone in hyperhaemolysis syndrome in sickle cell disease. Hematology 2004;9(5/6):433–436.
12. Win N., Doughty H., Telfer P., Wild B.J., Pearson T.C. Hyperhemolytic transfusion reaction in sickle cell disease. Transfusion 2001;41(3):323–328.
Neha H. Sickle Hyper-hemolytic Transfusion Reaction Syndrome. Perspectives in Medical Research 2018; 6(3):87-89.